A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration
A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration
The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
The trial was terminated early on April 12, 2013 due to an organizational decision, which was not based on safety or efficacy concerns. Subjects who were already enrolled into the study were followed.
Inclusion Criteria:
Exclusion Criteria:
Roseville, California 95661, United States
Santa Ana, California 92705, United States
Santa Ana, California 92705, United States
Altamonte Springs, Florida 32701, United States
West Palm Beach, Florida 33407, United States
East Setauket, New York 11733, United States
Lynbrook, New York 11563, United States
Rockville Centre, New York 11570, United States
Valley Stream, New York 11570, United States
WestMifflin, Pennsylvania 15122, United States
West Columbia, South Carolina 29169, United States
West Columbia, South Carolina 29169, United States